Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer
暂无分享,去创建一个
S. Carter | E. V. Van Allen | J. Lennerz | H. Willers | T. Hong | S. Wankowicz | David Liu | B. Reardon | A. Tracy | S. Kamran | R. Corcoran | J. Wo | C. Margolis | E. V. van Seventer | E. V. Van Seventer | Claire A. Margolis
[1] T. Helleday. Making immunotherapy 'cold' tumours 'hot' by chemotherapy-induced mutations-a misconception. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] C. Brennan,et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.
[3] R. Emerson,et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade , 2018, Nature Medicine.
[4] M. Rubin,et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer , 2018, The Journal of clinical investigation.
[5] F. Wenz,et al. Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math , 2018, Strahlentherapie und Onkologie.
[6] M. Moriyama,et al. Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma. , 2018, International journal of oral and maxillofacial surgery.
[7] K. Mouw,et al. Applying Precision Oncology Principles in Radiation Oncology. , 2018, JCO precision oncology.
[8] J. Sarkaria,et al. Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. , 2018, The Lancet. Oncology.
[9] Catherine C. Park,et al. The Future of Radiobiology. , 2018, Journal of the National Cancer Institute.
[10] Johannes Zimmermann,et al. Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis , 2018, Journal of Immunotherapy for Cancer.
[11] W. Guo,et al. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse , 2018, Journal of Hematology & Oncology.
[12] C. N. Coleman,et al. Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference. , 2017, International journal of radiation oncology, biology, physics.
[13] G. Getz,et al. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer , 2017, Nature Communications.
[14] J. Ajani,et al. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival—The University of Texas MD Anderson Cancer Center experience , 2017, Cancer.
[15] Andrew W. Lo,et al. Re-inventing drug development: A case study of the I-SPY 2 breast cancer clinical trials program. , 2017, Contemporary clinical trials.
[16] Barbara L. Smith,et al. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.
[17] Ryan Emerson,et al. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. , 2017, Cancer discovery.
[18] Jeffrey W. Clark,et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype , 2017, Journal of the National Cancer Institute.
[19] R. Mak,et al. Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. , 2017, Cancer research.
[20] C. Zahnow,et al. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. , 2017, Cancer discovery.
[21] Qian Wang,et al. The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer , 2017, Molecular Cancer.
[22] Davide Prandi,et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma , 2016, Nature Genetics.
[23] L. Garraway,et al. Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. , 2016, Cancer discovery.
[24] E. Winer,et al. Perils of the Pathologic Complete Response. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] L. Chin,et al. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. , 2016, Cancer discovery.
[26] Shixiu Wu,et al. Fractionated irradiation-induced EMT-like phenotype conferred radioresistance in esophageal squamous cell carcinoma , 2016, Journal of radiation research.
[27] A. Jemal,et al. Cancer treatment and survivorship statistics, 2016 , 2016, CA: a cancer journal for clinicians.
[28] C. N. Coleman,et al. Radiotherapy: Changing the Game in Immunotherapy. , 2016, Trends in cancer.
[29] Robert T. Jones,et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. , 2015, Cancer discovery.
[30] I. Jurisica,et al. A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patients , 2015, Cancer biology & therapy.
[31] Joshy George,et al. Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.
[32] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[33] Trevor J Pugh,et al. Oncotator: Cancer Variant Annotation Tool , 2015, Human mutation.
[34] Ash A. Alizadeh,et al. Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.
[35] N. Hacohen,et al. Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.
[36] S. Gabriel,et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. , 2014, Cancer discovery.
[37] David J Brenner,et al. The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? , 2014, International journal of radiation oncology, biology, physics.
[38] Steven J. M. Jones,et al. Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.
[39] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[40] J. Barnholtz-Sloan,et al. Gene expression profile is associated with chemoradiation resistance in rectal cancer , 2014, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[41] Takashi Akiyoshi,et al. Prediction of Response to Preoperative Chemoradiotherapy in Rectal Cancer by Using Reverse Transcriptase Polymerase Chain Reaction Analysis of Four Genes , 2014, Diseases of the colon and rectum.
[42] M. Kris,et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. , 2014, The Lancet. Oncology.
[43] Seon-Young Kim,et al. Novel single-nucleotide polymorphism markers predictive of pathologic response to preoperative chemoradiation therapy in rectal cancer patients. , 2013, International journal of radiation oncology, biology, physics.
[44] R. Nelson,et al. Mutations in Specific Codons of the KRAS Oncogene are Associated with Variable Resistance to Neoadjuvant Chemoradiation Therapy in Patients with Rectal Adenocarcinoma , 2013, Annals of Surgical Oncology.
[45] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[46] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..
[47] A. McCullough,et al. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing , 2013 .
[48] R. Weichselbaum,et al. The confluence of radiotherapy and immunotherapy , 2012, Front. Oncol..
[49] M. Bernstein,et al. In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer , 2012, Front. Oncol..
[50] Toshiaki Watanabe,et al. Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer , 2012, Surgery Today.
[51] Wendy S. W. Wong,et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..
[52] A. McKenna,et al. Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.
[53] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[54] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[55] Susmita Datta,et al. Surrogate variable analysis using partial least squares (SVA-PLS) in gene expression studies , 2012, Bioinform..
[56] M. Ychou,et al. A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer , 2011, The Pharmacogenomics Journal.
[57] Hoguen Kim,et al. Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer. , 2011, International journal of radiation oncology, biology, physics.
[58] Robert A. Weinberg,et al. Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.
[59] Kristian Cibulskis,et al. ContEst: estimating cross-contamination of human samples in next-generation sequencing data , 2011, Bioinform..
[60] Xutao Deng,et al. Chromosomal copy number alterations are associated with tumor response to chemoradiation in locally advanced rectal cancer , 2011, Genes, chromosomes & cancer.
[61] Hein Putter,et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. , 2011, The Lancet. Oncology.
[62] P. Lambin,et al. E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[63] V. Canzonieri,et al. Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy , 2011, The Pharmacogenomics Journal.
[64] M. Shimada,et al. Gene expression profile can predict pathological response to preoperative chemoradiotherapy in rectal cancer. , 2011, Cancer genomics & proteomics.
[65] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer , 2011, Nature Biotechnology.
[66] Jason M Doherty,et al. Tumorigenesis and Neoplastic Progression The Transcription Factor MIST 1 Is a Novel Human Gastric Chief Cell Marker Whose Expression Is Lost in Metaplasia , Dysplasia , and Carcinoma , 2010 .
[67] N. Petrelli,et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] T. Ried,et al. Chromosomal copy number changes of locally advanced rectal cancers treated with preoperative chemoradiotherapy. , 2009, Cancer genetics and cytogenetics.
[69] M. Aljurf,et al. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy. , 2008, Cancer research.
[70] Anne-Laure Boulesteix,et al. Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[71] J. Clements,et al. Epithelial—mesenchymal and mesenchymal—epithelial transitions in carcinoma progression , 2007, Journal of cellular physiology.
[72] O. Lund,et al. NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence , 2007, PloS one.
[73] H. Choi,et al. Microarray Gene Expression Profiling for Predicting Complete Response to Preoperative Chemoradiotherapy in Patients with Advanced Rectal Cancer , 2007, Diseases of the colon and rectum.
[74] Cheng Li,et al. Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.
[75] Hoguen Kim,et al. Oncologic Outcomes After Neoadjuvant Chemoradiation Followed by Curative Resection With Tumor-Specific Mesorectal Excision for Fixed Locally Advanced Rectal Cancer: Impact of Postirradiated Pathologic Downstaging on Local Recurrence and Survival , 2006, Annals of surgery.
[76] J. Pollard,et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. , 2006, Cancer research.
[77] Yoko Yamamoto,et al. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. , 2006, Cancer research.
[78] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[79] Rainer Fietkau,et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.
[80] T. Hickish,et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.
[81] T. Takayama,et al. Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. , 2001, Gastroenterology.
[82] W. Regine,et al. Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. , 2000, International journal of radiation oncology, biology, physics.
[83] M. Nakagawa,et al. Prognostic value of tumor‐associated macrophage count in human bladder cancer , 2000, International journal of urology : official journal of the Japanese Urological Association.
[84] T. Soussi. The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation , 2000, Annals of the New York Academy of Sciences.
[85] A. Harris,et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. , 1996, Cancer research.
[86] W. Enker,et al. Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] B. Vogelstein,et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. , 1990, Cancer research.
[88] Y. Nakamura,et al. Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.